A new US study has revealed the effectiveness of vaccination against pneumococcal infection in reducing the death rate in adults admitted to hospital with community acquired pneumonia.The study was published in April 15 edition of journal Clinical Infectious Diseases.
The findings, which were based on data from 62,918 adult patients with CAP between 1999 and 2003, showed that vaccinated patients were 40% - 70% less likely to die while hospitalized than unvaccinated people. In addition, vaccination reduced the median length of hospital stay by two days and was associated with a reduced risk of respiratory and kidney failure, cardiac arrest and sepsis syndrome.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze